108 related articles for article (PubMed ID: 11457435)
21. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
Uversky VN
J Biomol Struct Dyn; 2003 Oct; 21(2):211-34. PubMed ID: 12956606
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-like features of polyglutamine aggregates and their assembly kinetics.
Chen S; Berthelier V; Hamilton JB; O'Nuallain B; Wetzel R
Biochemistry; 2002 Jun; 41(23):7391-9. PubMed ID: 12044172
[TBL] [Abstract][Full Text] [Related]
23. Degradative organelles containing mislocalized alpha-and beta-synuclein proliferate in presenilin-1 null neurons.
Wilson CA; Murphy DD; Giasson BI; Zhang B; Trojanowski JQ; Lee VM
J Cell Biol; 2004 May; 165(3):335-46. PubMed ID: 15123735
[TBL] [Abstract][Full Text] [Related]
24. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains.
Schmidt ML; Schuck T; Sheridan S; Kung MP; Kung H; Zhuang ZP; Bergeron C; Lamarche JS; Skovronsky D; Giasson BI; Lee VM; Trojanowski JQ
Am J Pathol; 2001 Sep; 159(3):937-43. PubMed ID: 11549586
[TBL] [Abstract][Full Text] [Related]
25. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization.
Ruggeri FS; Adamcik J; Jeong JS; Lashuel HA; Mezzenga R; Dietler G
Angew Chem Int Ed Engl; 2015 Feb; 54(8):2462-6. PubMed ID: 25588987
[TBL] [Abstract][Full Text] [Related]
26. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
27. Forcing nonamyloidogenic beta-synuclein to fibrillate.
Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
[TBL] [Abstract][Full Text] [Related]
28. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases.
Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA
Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802
[TBL] [Abstract][Full Text] [Related]
29. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro.
Goers J; Uversky VN; Fink AL
Protein Sci; 2003 Apr; 12(4):702-7. PubMed ID: 12649428
[TBL] [Abstract][Full Text] [Related]
30. Cross-seeding effects of amyloid β-protein and α-synuclein.
Ono K; Takahashi R; Ikeda T; Yamada M
J Neurochem; 2012 Sep; 122(5):883-90. PubMed ID: 22734715
[TBL] [Abstract][Full Text] [Related]
31. Pathogenic effects of alpha-synuclein aggregation.
Lundvig D; Lindersson E; Jensen PH
Brain Res Mol Brain Res; 2005 Mar; 134(1):3-17. PubMed ID: 15790525
[TBL] [Abstract][Full Text] [Related]
32. Expression of alpha-synuclein in a human glioma cell line and its up-regulation by interleukin-1beta.
Tanji K; Imaizumi T; Yoshida H; Mori F; Yoshimoto M; Satoh K; Wakabayashi K
Neuroreport; 2001 Jul; 12(9):1909-12. PubMed ID: 11435921
[TBL] [Abstract][Full Text] [Related]
33. Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation.
Negro A; Brunati AM; Donella-Deana A; Massimino ML; Pinna LA
FASEB J; 2002 Feb; 16(2):210-2. PubMed ID: 11744621
[TBL] [Abstract][Full Text] [Related]
34. The aggregation and membrane-binding properties of an alpha-synuclein peptide fragment.
Madine J; Doig AJ; Middleton DA
Biochem Soc Trans; 2004 Dec; 32(Pt 6):1127-9. PubMed ID: 15506987
[TBL] [Abstract][Full Text] [Related]
35. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Lee VM; Giasson BI; Trojanowski JQ
Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
[TBL] [Abstract][Full Text] [Related]
36. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases.
Pawar AP; Dubay KF; Zurdo J; Chiti F; Vendruscolo M; Dobson CM
J Mol Biol; 2005 Jul; 350(2):379-92. PubMed ID: 15925383
[TBL] [Abstract][Full Text] [Related]
37. Liposome Enhanced Detection of Amyloid Protein Aggregates.
Kocsis I; Sanna E; Hunter CA
Org Lett; 2021 Feb; 23(3):647-650. PubMed ID: 33467854
[TBL] [Abstract][Full Text] [Related]
38. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro.
Cohlberg JA; Li J; Uversky VN; Fink AL
Biochemistry; 2002 Feb; 41(5):1502-11. PubMed ID: 11814343
[TBL] [Abstract][Full Text] [Related]
39. Detection of α-synuclein aggregates by fluorescence microscopy.
Hübinger S; Bannach O; Funke SA; Willbold D; Birkmann E
Rejuvenation Res; 2012 Apr; 15(2):213-6. PubMed ID: 22533435
[TBL] [Abstract][Full Text] [Related]
40. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions.
Popescu A; Lippa CF; Lee VM; Trojanowski JQ
Arch Neurol; 2004 Dec; 61(12):1915-9. PubMed ID: 15596612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
